Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas

CONTEXT: Patients with progressive metastatic pheochromocytomas (PHEOs) or sympathetic paragangliomas (SPGLs) face a dismal prognosis. Current systemic therapies are limited. OBJECTIVES: The primary end point was progression-free survival determined by RECIST 1.1 criteria or positron emission tomogr...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Ayala-Ramirez, Montserrat, Chougnet, Cecile N., Habra, Mouhammed Amir, Palmer, J. Lynn, Leboulleux, Sophie, Cabanillas, Maria E., Caramella, Caroline, Anderson, Pete, Al Ghuzlan, Abir, Waguespack, Steven G., Deandreis, Desirée, Baudin, Eric, Jimenez, Camilo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Endocrine Society 2012
Konular:
Endocrine Care
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3683800/
https://ncbi.nlm.nih.gov/pubmed/22965939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2012-2356
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller